B Cells RNA Silencing Guide

Master RNA Silencing in B Cells

Study antibody production and B cell lymphomas without activation artifacts

70-95%

Knockdown Efficiency

Preserved

Cell Viability

Preserved

BCR Signaling Intact

Why B Cells Are Critical for Immunology and Cancer Research

B lymphocytes (B cells) are professional antibody-producing cells and central mediators of humoral immunity [1,2]. B cells recognize antigens through the B cell receptor (BCR) complex (CD79A/B + membrane-bound immunoglobulin), undergo clonal expansion, and differentiate into antibody-secreting plasma cells or long-lived memory B cells [9]. This adaptive response provides antigen-specific immunity and immunological memory.

In addition to antibody production, B cells serve critical roles in autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis), B cell malignancies (diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma, follicular lymphoma, chronic lymphocytic leukemia [CLL]), and vaccine responses [10]. B cell lymphomas comprise approximately 85% of non-Hodgkin lymphomas, with DLBCL accounting for approximately 30-40% of NHL cases [11,12]. Key oncogenic drivers include MYC (characteristic t(8;14) translocation in Burkitt lymphoma) [13,15], BCL6 (transcriptional repressor frequently dysregulated in DLBCL) [14,16], and BCL2 (t(14;18) translocation characteristic of follicular lymphoma) [17].

The fundamental challenge: B cells are suspension cells with extremely low transfection efficiency. Primary human B cells achieve <5% lipofection efficiency due to minimal endocytic activity and robust lysosomal degradation [19,20]. Electroporation causes 40-60% cell death and induces unwanted B cell activation (BCR signaling, calcium flux, premature differentiation) [19,20]. Even established B cell lines (Raji, Daudi, BJAB) show only 15-30% electroporation efficiency with significant toxicity. This makes genetic studies of BCR signaling, class switch recombination, and lymphoma biology extremely difficult.

AUMsilence self-delivering ASO technology enables transfection-free B cell research. AUMsilence sdASOs enter cells via receptor-mediated endocytosis of their phosphorothioate-modified backbones [21,24], followed by intracellular trafficking and endosomal escape mechanisms that allow target RNA engagement via RNase H1-mediated cleavage [22,26,28], achieving effective gene knockdown in both primary B cells and B cell lines without affecting viability or activation state [30]. This enables: (1) BCR signaling pathway dissection (BTK, PLCγ2, SYK, CD79A/B) [3,4,5], (2) B cell lymphoma oncogene studies (BCL6, MYC, BCL2, PAX5) [14,15,16,17], (3) class switch recombination and somatic hypermutation (AID/AICDA, UNG, MSH2) [8], (4) plasma cell differentiation (BLIMP1/PRDM1, IRF4, XBP1) [9], (5) B cell survival pathways (BAFF-R, CD19, CD20, CD40) [6,7], (6) autoimmune disease mechanisms (IL-10, TGF-β, regulatory B cells).

Applications span B cell lymphoma biology, antibody discovery and optimization, autoimmune disease modeling, vaccine development, CAR-T target validation (CD19, CD20, BCMA) [18], and emerging CAR-B cell engineering (antibody-secreting engineered B cells for continuous therapeutic antibody production).

B cells produce antigen-specific antibodies and provide humoral immunity [1,2]

B cell lymphomas comprise ~85% of non-Hodgkin lymphomas including DLBCL, Burkitt, and follicular lymphoma [11,12,13]

Key oncogenes: MYC (Burkitt t(8;14)) [13,15], BCL6 (DLBCL) [14,16], BCL2 (follicular t(14;18)) [17]

Primary B cells show <5% lipofection efficiency with minimal endocytosis [19,20]

Electroporation causes 40-60% death and unwanted BCR activation artifacts [19,20]

AUMsilence achieves effective knockdown via receptor-mediated endocytosis [21,24] and RNase H1 cleavage [22,26,28]

Enables BCR signaling studies [3,4,5], lymphoma oncogene research [14,15,16], and class switching mechanisms [8]

Critical Challenges in B Cell Transfection

B cells present unique biological barriers that cause conventional transfection to fail or create experimental artifacts:

Suspension Cell Biology with Minimal Endocytic Activity

B cells grow in suspension (unlike adherent fibroblasts or epithelial cells) with limited pinocytosis [19]. Lipofection relies on endocytic uptake of lipoplexes; B cells exhibit 5-10 fold lower endocytosis than adherent cells. Primary human B cells (isolated from PBMCs or tonsils) achieve <5% lipofection efficiency even with optimized reagents [19,20]. This extremely low efficiency makes population-level gene silencing studies impossible with conventional transfection. Only a tiny fraction of cells take up siRNA/ASO, and these often show altered viability or activation state.

High Impact

Transfection-Induced BCR Activation and Premature Differentiation

Cationic lipids and electroporation can trigger B cell activation through stress response pathways [19]. Lipoplexes may stimulate BCR-independent calcium flux, activate downstream signaling (SYK, BTK, PLCγ2) [3,4,5], and induce activation markers (CD69, CD86, HLA-DR upregulation) within 4-6 hours. This creates experimental artifacts: studies examining naive B cell biology, BCR signal thresholds, or anergy/tolerance become unreliable because transfection itself activates cells. Moreover, electroporation can trigger premature plasma cell differentiation (BLIMP1 induction, immunoglobulin secretion) [9], confounding studies of B cell-to-plasma cell differentiation pathways.

High Impact

Severe Electroporation Toxicity and Membrane Damage

B cells are extremely sensitive to electroporation. High voltage pulses cause 40-60% immediate cell death (measured by Trypan blue or 7-AAD exclusion within 24h post-electroporation) [19,20]. Surviving B cells show compromised membrane integrity, leading to calcium dysregulation (critical for BCR signaling studies) [3] and altered responsiveness to B cell activators (anti-IgM, CD40L, CpG). Electroporation disrupts lipid rafts where BCR signaling complexes assemble [3], fundamentally altering signal transduction. This makes functional studies of BCR signaling, calcium flux, and downstream gene induction unreliable.

High Impact

Rapid Lysosomal Degradation of Delivered Cargo

B cells possess efficient endosomal-lysosomal systems (mature endosomes pH 5.5-6.0, lysosomes pH 4.5-5.0) with abundant nucleases and proteases. Lipoplexes and transfected nucleic acids are rapidly trafficked to acidic compartments and degraded before achieving cytoplasmic release. This reduces effective intracellular concentration of delivered cargo, requiring higher doses that exacerbate toxicity. The "endosomal escape problem" is particularly severe in B cells compared to other lymphocytes, limiting efficacy of conventional transfection even in the small fraction of cells that internalize reagents.

Medium Impact

B Cell Line Limitations and Non-Representative Biology

Commonly used B cell lines (Raji, Daudi, BJAB) are derived from Burkitt lymphoma and carry MYC translocations [13,15], constitutive BCR signaling mutations [4], and altered cell cycle checkpoints. While these lines are more transfectable than primary B cells (15-30% electroporation efficiency vs. <5%) [19,20], they do not represent normal B cell biology [1,2]. Raji cells have EBV infection, Daudi cells lack MHC Class I expression, and BJAB cells have disrupted TP53. Findings in these lines may not translate to primary human B cells, germinal center B cells, or other B cell lymphoma subtypes (DLBCL, mantle cell lymphoma, marginal zone lymphoma) [10,12,14].

Medium Impact

Developmental Stage-Dependent Transfection Variability

B cells exist in multiple developmental and activation states: naive B cells (resting, quiescent), germinal center B cells (rapidly dividing, undergoing somatic hypermutation and class switching), memory B cells (resting, antigen-experienced), plasmablasts (differentiating), and plasma cells (terminally differentiated, non-dividing antibody factories). Transfection efficiency varies dramatically: germinal center B cells show moderate efficiency (10-20% electroporation) due to active proliferation, while naive B cells (<5%) and plasma cells (<3%) are highly resistant. This makes it impossible to study B cell differentiation trajectories using conventional transfection: each stage requires different optimization, and transfection itself perturbs differentiation state.

High Impact

Method Comparison

Method	Efficiency	Viability	Pros	Cons
Lipofection (Cationic Lipid Reagents)	<5%	50-70%	Commercially available	Extremely low efficiency, can trigger BCR activation, calcium flux artifacts, premature differentiation
Electroporation	15-30%	40-60%	Moderate efficiency in cell lines	High cell death, membrane damage, disrupts BCR signaling, calcium dysregulation, expensive
Viral Vectors (Lentivirus, AAV)	40-60%	70-80%	Moderate efficiency, stable transduction	2-4 week production, expensive, B cells relatively resistant to viral transduction, integration risks
AUMsilence sdASO	70-95%	Preserved (>90%)	No transfection, no BCR activation artifacts, preserves calcium signaling, works in primary and lines, preserves differentiation state, no membrane damage	Transient knockdown (ideal for functional studies)

AUMsilence sdASO

The Ideal Solution for B Cell Gene Silencing

Why This Product?

AUMsilence self-delivering ASOs are uniquely suited for B cell research because they eliminate transfection-induced activation artifacts that plague conventional methods [19,20]. B cells are suspension cells with extremely low lipofection efficiency (<5%) and severe electroporation toxicity (40-60% death) [19,20]. Even minimal transfection can trigger unwanted BCR activation (calcium flux, CD69 upregulation, premature differentiation) [3,19]. AUMsilence preserves BCR signaling capacity, activation state, and differentiation potential while achieving effective gene knockdown through receptor-mediated endocytosis [21,24] followed by intracellular trafficking and RNase H1-mediated target engagement [22,26,28].

Key Benefits

Maintains High B Cell Viability

Preserves cell viability for extended functional assays: BCR signaling time courses, long-term antibody production (7-14 days), class switch recombination studies, B-T cell co-cultures. No membrane damage or activation artifacts.

Enables BCR Signaling Pathway Dissection

Knockdown BCR components (CD79A, CD79B), kinases (BTK, SYK, LYN), or effectors (PLCγ2, BLNK). Measure calcium flux, phospho-signaling, activation marker upregulation, proliferation. Validates therapeutic targets (BTK inhibitors like ibrutinib).

B Cell Lymphoma Biology Studies

Knockdown lymphoma oncogenes (MYC, BCL6, BCL2, PAX5) in B cell lines (Raji, Daudi) or primary lymphoma cells. Measure proliferation, apoptosis, BCR signaling addiction. Model lymphoma dependencies without long-term CRISPR knockout effects.

Class Switching and Antibody Production

Knockdown AID (AICDA) to block class switch recombination, BLIMP1 to prevent plasma cell differentiation, XBP1 to impair antibody secretion. Dissect antibody diversification mechanisms (somatic hypermutation, CSR) and plasma cell biology.

CAR-T Target Validation

Knockdown CD19 or CD20 in B cell lymphoma lines to model antigen loss escape. Test if lymphoma cells survive without CD19/CD20 (predict CAR-T resistance). Validate alternative targets (CD22, CD79A, CD79B).

Rapid Timeline for Target Validation

Test gene function in 3-5 days: isolate B cells, add ASO, validate knockdown, perform functional assays. No viral vector cloning, no electroporation optimization. Accelerates hypothesis testing in B cell biology.

Ideal For

Primary human B cells (CD19+ from peripheral blood, tonsils, lymph nodes)
B cell lines (Raji, Daudi, BJAB, SU-DHL-4, JeKo-1)
BCR signaling pathway dissection (BTK, SYK, PLCγ2, CD79A/B)
B cell lymphoma biology (DLBCL, Burkitt, follicular lymphoma, CLL, mantle cell)
Oncogene studies (MYC, BCL6, BCL2, PAX5, IRF4)
Class switch recombination and somatic hypermutation (AID/AICDA)
Plasma cell differentiation (BLIMP1, IRF4, XBP1)
Antibody production and optimization
B cell survival pathways (BAFF-R, CD19, CD40, BCL2)
Autoimmune disease mechanisms (regulatory B cells, IL-10, TGF-β)
CAR-T target validation (CD19, CD20, CD22 escape)
Emerging CAR-B cell engineering (antibody-secreting engineered B cells)

Learn More About AUMsilence sdASO

Alternative Products

AUMsaver toASO

When to use: Economy option for B cell line studies (Raji, Daudi, BJAB) and high-throughput screening. Recommended for non-critical optimization experiments before moving to primary B cells with AUMsilence.

Learn More →

AUMantagomir sdASO

When to use: For microRNA inhibition in B cells. Recommended for studying miR-155 (germinal center B cell proliferation, Burkitt lymphoma), miR-150 (B cell development), miR-181 (BCR signaling regulation).

Learn More →

Custom ASO Design Service

When to use: For novel B cell targets or multi-gene lymphoma panels. AUM scientists design and validate 3-5 ASO candidates per target, optimized for human sequences.

Learn More →

AUMsilence Protocols for B Cells

Optimized protocols for primary human B cells, B cell lines (Raji, Daudi, BJAB), and B cell differentiation studies. No transfection reagents required.

Quick Start Protocol (All B Cell Types)

Culture B cells at 0.5-1 × 10⁶ cells/mL in appropriate medium (RPMI + 10% FBS for primary, RPMI + 20% FBS for Raji/Daudi)
Add AUMsilence sdASO directly to culture medium at 2-5 μM final concentration (no transfection reagent required)
Incubate 48-72 hours at 37°C, 5% CO₂
Validate knockdown by qRT-PCR (48h) and flow cytometry or Western blot (72h)
Perform functional assays: BCR signaling (calcium flux), antibody production (ELISA), proliferation (CFSE), differentiation (CD27, CD38, CD138)

Cell-Type-Specific Protocols

Primary Human B Cells (CD19+ from PBMCs)

Freshly isolated or cryopreserved peripheral blood B cells

B Cell Isolation from PBMCs

Isolate B cells from PBMCs using CD19 magnetic bead positive selection. Negative selection alternative: deplete T cells (CD3), monocytes (CD14), and NK cells (CD56). CD19+ selection yields 95-98% purity. Typical yield: 5-15% of PBMCs are B cells. Can also isolate from tonsils (higher yield, more germinal center B cells) or lymph nodes.

Materials: RPMI-1640 + 10% FBS + 1% Pen/Strep, CD19 magnetic beads

Note: Primary B cells are fragile; handle gently. Freshly isolated B cells are quiescent (naive) and require activation for proliferation studies. Do NOT use T cell media (RPMI works for both).

Day 0

Primary B Cell Culture (Unstimulated or Activated)

Seed freshly isolated B cells at 0.5-1 × 10⁶ cells/mL in complete RPMI. For unstimulated (naive) B cells: culture without additional stimulation (short-term studies, 2-4 days). For activated B cells: add B cell activators at Day 0: (1) anti-IgM F(ab')₂ (10 μg/mL, BCR crosslinking), (2) CD40L (1 μg/mL, co-stimulation), (3) CpG ODN 2006 (2.5 μM, TLR9 agonist), (4) BAFF and APRIL (50-100 ng/mL, survival signals). Activation induces proliferation (measure by CFSE dilution) and upregulation of activation markers (CD69, CD86, CD25).

Materials: RPMI + FBS, anti-IgM, CD40L, CpG, BAFF, APRIL

Note: Naive B cells survive 2-4 days without activation and undergo apoptosis without survival signals. Activated B cells proliferate and survive 7-14 days. Plan ASO treatment timing based on activation state.

Day 0-2

AUMsilence Treatment of Primary B Cells

At Day 1-2 (24-48h post-isolation, with or without activation), add AUMsilence sdASO directly to culture at 2-5 μM. For 500 μL culture (24-well), add 1-2.5 μL of 1 mM AUMsilence stock. No media change required. AUMsilence sdASOs enter cells via receptor-mediated endocytosis of their phosphorothioate-modified backbones, followed by intracellular trafficking; a small fraction escapes endosomes to reach the cytosol and nucleus where target engagement occurs via RNase H1.

Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)

Note: Start with 2-5 μM for primary B cells (lower than T cells or macrophages). B cells are smaller with lower cytoplasmic volume. Higher concentrations may cause off-target effects. Knockdown efficiency: 70-95% (target-dependent; empirical validation required). Results vary by target gene stability, expression level, and cell division rate.

Day 1-2

Incubation and Monitoring

Incubate 48-72h at 37°C, 5% CO₂. Monitor cell density and viability daily (>90% viability expected with proper culture conditions). B cells remain in suspension. Do NOT change medium unless specific assay requires it (loss of secreted factors).

Materials: Humidified CO₂ incubator

Note: Peak mRNA knockdown at 48h, protein knockdown at 72h. Functional assays typically at 72h-96h post-ASO. For proliferation studies, activated B cells divide every 18-24h.

Days 1-4

Validation and Functional Assays

At 48h: qRT-PCR for mRNA knockdown (expect 60-90% reduction depending on target). At 72h: flow cytometry for surface markers (CD19, CD20, BAFF-R, BCR components) or intracellular proteins (BCL6, PAX5, BLIMP1, IRF4). Functional assays at 72-96h: (1) BCR signaling: anti-IgM stimulation, measure calcium flux (Indo-1 or Fluo-4 by flow), phospho-SYK/BTK/PLCγ2 by phospho-flow, (2) Proliferation: CFSE dilution after CD40L+anti-IgM stimulation, (3) Antibody production: culture with activators 5-7 days, measure IgM/IgG/IgA in supernatants by ELISA, (4) Differentiation: plasma cell markers (CD27high CD38high CD138+), measure by flow.

Materials: Flow antibodies, calcium indicators, ELISA kits, CFSE

Note: AUMsilence preserves BCR signaling unless targeting signaling components. Calcium flux is gold standard for BCR function and should be normal in ASO-treated cells (unless targeting calcium pathway genes).

Days 3-7

Raji Cells (Burkitt Lymphoma B Cell Line)

EBV-positive Burkitt lymphoma cell line, most common B cell research model

Raji Cell Culture

Culture Raji cells in RPMI-1640 + 10-20% FBS. Cells grow in suspension, doubling time 20-24h. Maintain at 2-8 × 10⁵ cells/mL. Split 1:3 to 1:5 every 2-3 days. Raji cells are Burkitt lymphoma line with MYC translocation t(8;14), constitutive BCR signaling, and EBV positivity (express EBV latency proteins EBNA1, LMP1, LMP2).

Materials: RPMI-1640 + 10-20% FBS

Note: Raji cells are hardy B cell line and easier to culture than primary B cells. Used extensively for BCR signaling studies, lymphoma biology, and CAR-T target validation (CD19, CD20).

Maintain stock culture

AUMsilence Treatment of Raji Cells

Seed Raji at 3-5 × 10⁵ cells/mL in fresh medium 24h before ASO treatment. Add AUMsilence at 2-5 μM final concentration. AUMsilence sdASOs enter cells via receptor-mediated endocytosis. Lower concentration (2-3 μM) often sufficient due to rapid proliferation.

Materials: AUMsilence sdASO

Note: Raji cells useful for screening applications, BCR signaling pathway dissection, lymphoma oncogene studies (BCL6, MYC, BCL2). Validate key findings in primary B cells.

Day 0-3

Lymphoma Biology Applications

Raji is Burkitt lymphoma model for studying MYC-driven biology: (1) MYC knockdown reduces proliferation 60-80% and induces apoptosis (measure annexin V/7-AAD), (2) BCL6 knockdown (DLBCL transcriptional repressor also expressed in Burkitt), (3) BCR signaling addiction: knockdown CD79A, CD79B, SYK, or BTK and measure apoptosis (Burkitt cells depend on tonic BCR signaling), (4) CD19/CD20 knockdown for CAR-T target validation (measure surface receptor loss, predict antigen escape).

Materials: Standard validation reagents, apoptosis assays

Note: Raji represents Burkitt biology (MYC-driven) but NOT other B cell lymphomas (DLBCL, follicular). Use appropriate cell lines for specific lymphoma subtypes: SU-DHL-4 (DLBCL), JeKo-1 (mantle cell), and WSU-DLCL2 (activated B-cell DLBCL).

Days 2-5

Daudi Cells (Burkitt Lymphoma, MHC Class I-Deficient)

Burkitt lymphoma line lacking MHC Class I (B2M mutation)

Daudi Cell Culture and Properties

Culture Daudi in RPMI-1640 + 10-20% FBS. Suspension culture, doubling time 24-30h. Maintain at 2-8 × 10⁵ cells/mL. Daudi is Burkitt lymphoma (like Raji) but with B2M (beta-2 microglobulin) mutation and lacks surface MHC Class I (HLA-A, -B, -C). This makes Daudi sensitive to NK cell killing (loss of "self" recognition) but resistant to CD8+ T cell recognition.

Materials: RPMI-1640 + FBS

Note: Daudi useful for: NK cell target studies (MHC Class I-negative), B cell intrinsic biology (without MHC Class I signaling confounds), BCR signaling, apoptosis pathways.

Maintain stock culture

AUMsilence in Daudi Cells

Add AUMsilence at 2-5 μM final concentration to Daudi cultures. Use for studies where MHC Class I absence is advantageous: BCR signaling without T cell interactions, B cell-intrinsic apoptosis (no CTL confound), NK-B cell interactions (Daudi is NK cell target).

Materials: AUMsilence sdASO

Note: Daudi vs. Raji selection: use Daudi if studying B cell-intrinsic pathways without MHC Class I/T cell confounds. Use Raji for more general Burkitt lymphoma biology.

Day 0-3

Plasma Cell Differentiation Studies

B cell to plasma cell differentiation and antibody production

Inducing Plasma Cell Differentiation from Primary B Cells

Activate naive B cells with CD40L (1 μg/mL) + IL-21 (50 ng/mL) + IL-4 (10 ng/mL) for 5-7 days to induce plasmablast/plasma cell differentiation. Alternatively: CpG (2.5 μM) + IL-21 + IL-2 (20 U/mL) for rapid differentiation (3-5 days). Differentiation markers: CD27 (memory B cell/plasmablast), CD38 (plasma cell), CD138/syndecan-1 (mature plasma cell), loss of CD20, upregulation of BLIMP1 (master plasma cell transcription factor), IRF4, XBP1 (unfolded protein response factor required for antibody secretion).

Materials: CD40L, IL-21, IL-4, CpG, IL-2

Note: Plasma cell differentiation is terminal: cells stop dividing and massively expand ER for high-rate antibody production. Timing critical for ASO treatment depending on experimental question.

Day 0-7

ASO Treatment for Differentiation Pathway Dissection

Two experimental strategies: (1) Pre-differentiation knockdown: add AUMsilence at Day 0 (before differentiation stimuli), test if target gene REQUIRED for differentiation (e.g., BLIMP1, IRF4 knockdown prevents plasma cell formation), (2) Post-differentiation knockdown: differentiate for 3-4 days, add AUMsilence, test function in established plasmablasts/plasma cells (e.g., XBP1 knockdown in differentiated cells reduces antibody secretion without affecting differentiation per se).

Materials: AUMsilence targeting BLIMP1, IRF4, XBP1, PAX5 (represses plasma cell genes)

Note: BLIMP1 (encoded by PRDM1) is master regulator; knockdown blocks plasma cell differentiation. PAX5 maintains B cell identity; knockdown allows plasma cell differentiation. IRF4 required for plasma cell maturation. XBP1 required for ER expansion and antibody secretion.

Day 0 or Day 3-4

Antibody Production Measurement

At Day 5-7 post-differentiation, measure secreted antibodies in culture supernatants by ELISA: total IgM, IgG, IgA (isotype-specific ELISA). For class switching studies (IgM → IgG or IgA), measure class switch recombination by: (1) flow cytometry for surface IgG+ or IgA+ cells, (2) qRT-PCR for germline transcripts (Iγ, Iα; precede switch recombination), (3) chromosome conformation capture (3C) to detect recombined heavy chain loci.

Materials: ELISA kits (IgM, IgG, IgA), flow antibodies (anti-IgG, anti-IgA)

Note: Class switch recombination (CSR) requires AID (AICDA, activation-induced cytidine deaminase). AID knockdown prevents class switching, and cells remain IgM+. CSR induced by CD40L + IL-4 (IgG1/IgE), CD40L + TGF-β (IgA), or CD40L + IFN-γ (IgG2a in mice).

Days 5-7

BCR Signaling and Calcium Flux Studies

Dissect BCR signal transduction pathways

BCR Signaling Component Knockdown

Treat primary B cells or Raji cells with AUMsilence targeting BCR signaling components: (1) Proximal: CD79A (Igα) and CD79B (Igβ); ITAM-containing signaling subunits, (2) Kinases: LYN, SYK, BTK, (3) Adapters and effectors: BLNK (SLP-65), PLCγ2, VAV1. Allow 48-72h for knockdown. Validate by Western blot (phospho-SYK Tyr525/526, phospho-BTK Tyr223, phospho-PLCγ2 Tyr1217).

Materials: AUMsilence targeting BCR signaling genes

Note: BTK (Bruton's tyrosine kinase) is clinical target. Ibrutinib (BTK inhibitor) approved for CLL, mantle cell lymphoma, and Waldenstrom's. Genetic knockdown validates BTK requirement before drug studies.

Day 0-3

BCR Stimulation and Calcium Flux Measurement

At 72h post-ASO, stimulate BCR and measure calcium flux. Load B cells with calcium indicator (Fluo-4 AM or Indo-1 AM, 30 min at 37°C), wash, baseline 30-60 sec, then add anti-IgM F(ab')₂ (10 μg/mL, BCR crosslinking). Measure calcium flux by flow cytometry (kinetic measurement, Indo-1 ratiometric) or plate reader (population average). BCR stimulation triggers rapid calcium release from ER (within 10-30 sec) followed by sustained calcium influx (store-operated calcium entry, SOCE).

Materials: Fluo-4 AM, Indo-1 AM, anti-IgM F(ab')₂, flow cytometer with kinetic capability

Note: Calcium flux is hallmark of BCR activation. BTK or PLCγ2 knockdown abolishes calcium response. SYK knockdown severely reduces calcium flux. CD79A/B knockdown (BCR complex itself) eliminates response. AUMsilence preserves calcium machinery and allows authentic dissection of signaling requirements.

Day 3

Downstream Signaling and Gene Induction

After BCR stimulation (anti-IgM, 6-24h), measure downstream events: (1) Phospho-flow: intracellular staining for phospho-ERK1/2 (Thr202/Tyr204), phospho-AKT (Ser473), and phospho-S6 (Ser235/236); measure by flow cytometry in fixed/permeabilized cells, (2) Activation markers: CD69, CD86, CD25 surface upregulation (flow cytometry, 18-24h post-BCR stimulation), (3) Proliferation: CFSE dilution (requires CD40L co-stimulation for sustained proliferation, BCR alone gives limited division).

Materials: Phospho-flow antibodies, activation marker antibodies, CFSE

Note: BCR signaling activates multiple pathways: calcium-NFAT (transcription), NF-κB (survival and activation), PI3K-AKT (metabolism and survival), and MAPK-ERK (proliferation). Knockdown of pathway-specific components dissects signaling logic.

Days 3-4

Essential Controls for B Cell Experiments

Untreated B Cells: Baseline BCR responsiveness, surface marker expression, antibody production

Culture identically without ASO. Critical for confirming no activation artifacts from ASO treatment.

Non-Targeting Control ASO: Control for non-specific ASO effects on B cell biology

Use AUM non-targeting control at 2-5 μM. Verifies phenotypic changes are target-specific. Critical for BCR signaling studies (ensure no non-specific calcium flux alterations).

Positive Control for BCR Signaling: Validate BCR activation capacity

Stimulate with anti-IgM F(ab')₂ (10 μg/mL) + CD40L (1 μg/mL) for robust activation. Measure calcium flux, CD69/CD86 upregulation, and proliferation. Ensures B cells functionally competent.

Activation State Monitoring: Ensure ASO does not induce unwanted activation

Measure CD69, CD86, HLA-DR by flow cytometry at 24-48h post-ASO. Compare untreated, non-targeting control, experimental ASO. Should be equivalent (no activation from ASO itself).

Optimization Strategies for B Cell Applications

ASO Concentration

Recommendation: Start with 2-5 μM for primary B cells and B cell lines. Lower than T cells (10-15 μM) due to smaller cell size and cytoplasmic volume.

Rationale: B cells are smaller than T cells or macrophages. Lower ASO concentration achieves equivalent intracellular concentration with reduced off-target risk. Test concentration range of 2-10 μM if needed.

Incubation Time

Recommendation: 48h for mRNA validation, 72h for protein validation and functional assays. B cells proliferate rapidly when activated (18-24h doubling); monitor proliferation dilution effect.

Rationale: Protein half-life varies: surface receptors (CD19, CD20, 24-48h), signaling proteins (BTK, SYK, 12-24h), transcription factors (BCL6, PAX5, 6-12h). Plan timing accordingly.

Activation vs. Naive B Cells

Recommendation: Naive B cells: short-term studies (2-4 days with limited survival without activation). Activated B cells: longer studies (7-14 days, proliferate and survive with CD40L, CpG, or BAFF). Choose based on biological question.

Rationale: Naive B cells represent resting peripheral B cells (tolerance, anergy, baseline BCR signaling). Activated B cells represent germinal center-like state (proliferation, class switching, differentiation).

Primary B Cells vs. Cell Lines

Recommendation: Primary B cells for translational studies, authentic BCR signaling, antibody production, class switching. B cell lines (Raji, Daudi) for screening, mechanistic studies, lymphoma biology.

Rationale: Primary B cells represent authentic biology but show donor variability and limited lifespan. Cell lines consistent but carry oncogenic mutations (MYC translocation, BCR signaling alterations). Validate key findings in both.

Serum Considerations

Recommendation: Standard 10-20% FBS optimal for B cells. Higher serum (20%) supports better survival of primary B cells. Serum proteins do not inhibit ASO uptake via receptor-mediated endocytosis.

Rationale: B cells more demanding than T cells; higher serum beneficial. Phosphorothioate ASOs bind serum proteins but this does not prevent cellular uptake. No serum starvation required (unlike lipofection).

Troubleshooting

Low Knockdown Efficiency (<50% in Primary B Cells)

Unwanted B Cell Activation (CD69, CD86 Upregulation)

Measure activation markers (CD69, CD86, HLA-DR) in untreated, non-targeting control ASO, and experimental ASO groups
If activation in both ASO groups: endotoxin or TLR9 issue. Use fresh ASO, verify <0.1 EU/mL endotoxin, reduce concentration to 2-3 μM
If activation only in experimental ASO: expected if targeting negative regulators (e.g., CD22, FcγRIIB). Document as on-target effect
Include calcium flux assay: non-specific activation shows calcium flux without BCR stimulation

Rapid B Cell Death or Loss of Viability

No Effect on BCR Signaling Despite Knockdown

Verify protein knockdown by Western blot or flow cytometry (not just mRNA by qRT-PCR)
Extend incubation to 96h for stable proteins
Test positive control: BTK or SYK knockdown abolishes calcium flux (well-validated)
Consider dual knockdown if pathway redundant (e.g., LYN + FYN both contribute to BCR signaling)
Use sensitive calcium flux assay (flow cytometry-based, single-cell resolution) rather than population average

High Donor-to-Donor Variability (Primary B Cells)

Class Switch Recombination Not Occurring Despite Differentiation Stimuli

Verify AID expression by qRT-PCR (should be highly upregulated 24-48h after CD40L + IL-4 stimulation)
Ensure robust CD40L stimulation (1 μg/mL) + cytokine (IL-4 10-20 ng/mL for IgG1)
Measure proliferation (CFSE dilution); class switching occurs during cell division
Positive control: CpG + IL-21 (potent CSR inducer)
Measure germline transcripts (Iγ, Iα by qRT-PCR); induced before switch recombination, confirms signaling intact

Validation Methods for B Cell Knockdown

Comprehensive validation ensures robust B cell biology insights. AUMsilence preserves viability and BCR signaling for all downstream assays.

Quantitative RT-PCR (qRT-PCR)

Purpose: Gold standard for mRNA knockdown quantification

Protocol: Extract total RNA at 48h post-ASO treatment using TRI Reagent or column-based RNA extraction kit. Synthesize cDNA (1 μg RNA input). Perform qPCR with target-specific primers (SYBR Green or probe-based detection). Normalize to housekeeping genes (GAPDH, ACTB, 18S rRNA). Calculate fold-change using ΔΔCt method.

Expected Results: Knockdown efficiency: 70-95% mRNA reduction (target-dependent; empirical validation required). Results vary by target gene stability, expression level, and cell division rate.

Tips: For BCR signaling studies, include activation markers (CD69, CD86) to verify no unwanted activation from ASO treatment itself (compare to non-targeting control). For differentiation studies, include BLIMP1, PAX5, and XBP1 to track differentiation state.

Flow Cytometry (Surface and Intracellular Proteins)

Purpose: Validate receptor knockdown and track B cell activation/differentiation

Protocol: At 72h post-ASO, stain live B cells for surface markers (CD19, CD20, CD79A, IgM, IgG, IgA, CD27, CD38, CD138, BAFF-R). For intracellular proteins: fix (4% PFA, 15 min), permeabilize (0.1% saponin or commercial permeabilization buffer), stain (BCL6, PAX5, BLIMP1, IRF4, intracellular Ig). Include viability dye.

Expected Results: Protein reduction varies by target (measured by MFI shift). High viability expected when proper culture conditions maintained.

Tips: Gate on live, CD19+ B cells (CD19 is universal B cell marker and lost only in plasma cells). For differentiation studies: naive (IgD+ CD27-), memory (CD27+ IgD-), plasmablasts (CD27high CD38high), and plasma cells (CD27high CD38high CD138+). If MFI not shifting despite mRNA knockdown, extend to 96h (long-lived proteins).

Calcium Flux Assay (BCR Signaling)

Purpose: Validate BCR signaling capacity and pathway knockdown effects

Protocol: Load B cells with calcium indicator (Indo-1 AM 2 μM, 30 min at 37°C, or Fluo-4 AM 1 μM). Wash, resuspend in HBSS + calcium. Baseline 30-60 sec, add anti-IgM F(ab')₂ (10 μg/mL), measure calcium flux by flow cytometry (kinetic, acquire continuously for 5-10 min). For plate reader: measure population average at 488/520 nm (Fluo-4). Indo-1 is ratiometric (405 nm excitation, measure 525 nm/450 nm ratio) and preferred for flow cytometry.

Expected Results: Untreated or non-targeting control: robust calcium flux (peak 200-400% increase over baseline within 30-60 sec). BTK or PLCγ2 knockdown: calcium flux abolished (80-90% reduction). SYK knockdown: calcium flux severely reduced (60-80% reduction).

Tips: Calcium flux is gold standard for BCR function. AUMsilence-treated B cells show normal calcium flux unless targeting calcium pathway genes. Critical to verify no membrane damage (electroporation causes calcium leak even without BCR stimulation). Include ionomycin (1 μM) as positive control at end of assay: bypasses BCR and confirms calcium indicator functional.

Phospho-Flow Cytometry

Purpose: Measure BCR signaling pathway activation at single-cell resolution

Protocol: Stimulate B cells with anti-IgM F(ab')₂ (10 μg/mL) for 0-30 min. Fix immediately (4% PFA, 10 min at 37°C), permeabilize (methanol, -20°C, 30 min or commercial phospho-flow permeabilization buffer), stain with phospho-specific antibodies: phospho-SYK (Tyr525/526), phospho-BTK (Tyr223), phospho-PLCγ2 (Tyr1217), phospho-ERK1/2 (Thr202/Tyr204), phospho-AKT (Ser473). Analyze in CD19+ live B cells.

Expected Results: Kinetics: phospho-SYK peaks 1-3 min, phospho-BTK 2-5 min, phospho-PLCγ2 3-5 min, phospho-ERK 10-20 min. Knockdown of upstream components reduces downstream phosphorylation.

Tips: Phospho-flow is powerful for BCR signaling studies: single-cell resolution and multiple phospho-proteins simultaneously. Critical: fix IMMEDIATELY after stimulation (phosphorylation is transient and peaks within minutes). Include unstimulated control (baseline phosphorylation). Methanol permeabilization preferred for phospho-epitopes (better epitope preservation than detergent-based perm).

Antibody Production (ELISA)

Purpose: Measure secreted antibody levels in differentiation studies

Protocol: Collect culture supernatants at Day 5-7 post-differentiation (CD40L + IL-21). Centrifuge (10,000g, 5 min) to remove cells. Perform sandwich ELISA for total IgM, IgG, IgA (isotype-specific capture and detection antibodies). For antigen-specific antibodies: coat plates with antigen, detect bound Ig. Normalize to cell number (count viable cells) or to IgM as internal control (IgM production continues during class switching).

Expected Results: Plasma cells are highly efficient antibody secretors. Day 7 culture supernatants contain measurable IgM and IgG (after class switching). BLIMP1 or XBP1 knockdown reduces antibody secretion. AID knockdown prevents class switching (IgM remains high, IgG/IgA low).

Tips: Culture B cells at higher density for antibody production studies (5-10 × 10⁵/mL); paracrine support enhances differentiation. For class switching: measure IgG subclasses (IgG1, IgG2, IgG3, IgG4); different cytokines induce different subclasses. IL-4 → IgG1/IgE, IFN-γ → IgG3, TGF-β → IgA.

Proliferation Assays (CFSE Dilution)

Purpose: Measure B cell division and proliferation after activation

Protocol: Label B cells with CFSE (5 μM, 10 min at 37°C), wash extensively. Culture with activators (CD40L + anti-IgM, or CpG + IL-21). Analyze CFSE dilution by flow cytometry at Day 3-5. Each division halves CFSE intensity. Use proliferation modeling software to calculate division index, proliferation index.

Expected Results: Activated B cells: 3-5 divisions by Day 5 (expect 3-5 CFSE peaks). MYC or cyclin knockdown reduces proliferation (fewer divisions). BCR signaling component knockdown may reduce proliferation (if BCR required for activation).

Tips: CFSE dilution is gold standard for proliferation: single-cell resolution and tracks cell generations. Critical: wash CFSE thoroughly (residual extracellular CFSE continues to label cells and obscures divisions). Include unstimulated control (should not divide). For plasmablast studies: late divisions (generation 4-5) preferentially differentiate.

Critical Controls for B Cell Validation

Untreated B Cells

Purpose: Baseline BCR signaling, surface marker expression, proliferation, antibody production

Culture identically without ASO. Essential for demonstrating ASO preserves B cell function and does not cause activation.

Non-Targeting Control ASO

Purpose: Control for non-specific ASO effects on B cell biology

Use AUM non-targeting control at 2-5 μM (match experimental ASO concentration and timing). Verifies phenotypic changes are target-specific, not ASO-related. Critical for BCR signaling studies.

Positive Control for BCR Activation

Purpose: Validate B cells are functionally competent

Stimulate with anti-IgM F(ab')₂ (10 μg/mL) + CD40L (1 μg/mL) for robust activation. Measure calcium flux, CD69/CD86 upregulation, and proliferation. If positive control fails, B cells are not functional (isolation or culture issue).

Activation State Monitoring

Purpose: Ensure ASO does not induce unwanted B cell activation

Measure CD69, CD86, HLA-DR by flow cytometry at 24-48h post-ASO. Compare untreated, non-targeting control, and experimental ASO. Should be equivalent unless targeting negative regulators (CD22, FcγRIIB; knockdown causes activation).

Differentiation State Tracking

Purpose: For plasma cell studies, track differentiation progression

Measure CD27, CD38, CD138 (plasma cell markers), BLIMP1, IRF4 (intracellular transcription factors). Document differentiation kinetics: Day 0 (naive), Day 3 (activated), Day 5 (plasmablasts), Day 7 (early plasma cells).

Best Practices

Use biological triplicates (n=3 independent experiments) with different donor PBMC preparations for primary B cells
Validate knockdown at both mRNA (qRT-PCR, 48h) and protein (flow/Western, 72h) levels
For BCR signaling studies, include calcium flux assay (gold standard for BCR function)
Monitor activation state (CD69, CD86) to ensure no artifacts from ASO treatment
For differentiation studies, track markers (CD27, CD38, CD138) at multiple timepoints
Include survival signals (BAFF, APRIL, or CD40L) for primary B cell cultures to prevent apoptosis
Report viability, activation state, and differentiation state in all publications

Research Applications for B Cell Biology

AUMsilence enables diverse applications across B cell lymphomas, immunology, and antibody development.

B Cell Lymphoma Biology (4 applications)

Study oncogene dependencies and therapeutic targets in B cell malignancies

DLBCL (Diffuse Large B-Cell Lymphoma) Oncogene Studies

Approach: Knockdown DLBCL oncogenes in cell lines or primary DLBCL cells [12,14]: (1) BCL6 (transcriptional repressor) [16]; knockdown may induce differentiation and apoptosis, (2) MYC (frequently rearranged in double-hit DLBCL) [15]; knockdown reduces proliferation, (3) BCL2 (anti-apoptotic, t(14;18) translocation) [17]; knockdown induces apoptosis and potentially synergizes with venetoclax. Measure proliferation (CFSE, BrdU), apoptosis (annexin V/7-AAD), and differentiation (CD138, BLIMP1).

AUM Advantage: Genetic validation of oncogene addiction before committing to targeted therapies (BCL6 inhibitors, BCL2 inhibitors like venetoclax, MYC inhibitors in development). Transient knockdown models drug treatment (reversible) better than permanent CRISPR knockout.

Burkitt Lymphoma MYC Dependency

Approach: Raji and Daudi are Burkitt lymphoma lines with characteristic MYC t(8;14) translocation [13,15]. MYC knockdown with AUMsilence can lead to growth inhibition and apoptosis induction. Test if phenotype can be rescued by overexpressing downstream MYC targets to validate direct MYC dependency.

AUM Advantage: Burkitt lymphoma is MYC-driven malignancy [13,15]; MYC knockdown validates MYC as therapeutic target. No direct MYC inhibitors approved yet, but genetic validation supports drug development efforts.

BCR Signaling Addiction in Lymphomas

Approach: Many B cell lymphomas depend on tonic (chronic) BCR signaling for survival [4,6]. Knockdown BCR components (CD79A, CD79B), proximal kinases (SYK, LYN), or BTK in lymphoma cell lines [3,5]. Measure apoptosis: BCR-addicted lymphomas undergo apoptosis within 24-48h. Test in activated B-cell-like (ABC) DLBCL (high BCR dependence) vs. germinal center B-cell-like (GCB) DLBCL (lower BCR dependence) [12,14].

AUM Advantage: BTK inhibitors (ibrutinib, acalabrutinib) approved for CLL, mantle cell lymphoma, Waldenstrom's [5,6]. Genetic knockdown validates BTK requirement and predicts clinical response. Can test BCR pathway components systematically to identify alternative targets.

CD19 and CD20 Loss Mechanisms (CAR-T Escape)

Approach: CD19 and CD20 are primary CAR-T and antibody therapy targets. Knockdown CD19 or CD20 in B cell lymphoma lines (Raji, Daudi). Measure: (1) surface receptor loss (flow cytometry), (2) cell survival: do lymphoma cells survive without CD19/CD20 (predicts antigen-loss escape), (3) alternative target expression: measure CD22, CD79A, CD79B (potential targets for CD19/CD20-loss relapse).

AUM Advantage: CD19-negative relapse occurs in 20-40% of CAR-T patients. Genetic knockdown models antigen loss and tests if lymphoma cells remain viable (predicts resistance). Identifies compensation mechanisms and alternative targets.

BCR Signaling Mechanisms (3 applications)

Dissect B cell receptor signal transduction and regulation

Proximal BCR Signaling (CD79A/B, SYK, BTK)

Approach: Knockdown proximal BCR signaling components: (1) CD79A or CD79B (Igα/Igβ); eliminates BCR complex formation, no calcium flux, (2) LYN (SRC family kinase); phosphorylates CD79 ITAMs, initiates signaling, (3) SYK (spleen tyrosine kinase); binds phosphorylated ITAMs, amplifies signal, (4) BTK (Bruton's tyrosine kinase); activates PLCγ2. Measure calcium flux (Indo-1, Fluo-4), phospho-flow (phospho-SYK, phospho-BTK, phospho-PLCγ2), and activation markers (CD69, CD86).

AUM Advantage: BCR signaling hierarchy well-studied but genetic validation in primary human B cells limited due to transfection challenges. AUMsilence enables systematic pathway dissection in authentic context. Validates therapeutic targets: BTK inhibitors (ibrutinib), SYK inhibitors (fostamatinib, entospletinib) in clinical use or trials.

Calcium Signaling and NFAT Activation

Approach: Knockdown calcium pathway components: PLCγ2 (generates IP3 → calcium release from ER), STIM1/ORAI1 (store-operated calcium entry, SOCE), calcineurin (phosphatase, activates NFAT transcription factors). Stimulate BCR (anti-IgM), measure calcium flux (immediate, 0-5 min) and NFAT nuclear translocation (30-60 min, immunofluorescence or NFAT-luciferase reporter).

AUM Advantage: Calcium signaling is central BCR output and controls transcription (NFAT), cell survival, and proliferation. Electroporation disrupts calcium homeostasis (membrane damage), but AUMsilence preserves it. Enables authentic calcium signaling studies.

Negative Regulators of BCR Signaling

Approach: Knockdown negative regulators to test signal amplification: (1) CD22 (co-inhibitory receptor, recruits SHP-1 phosphatase), (2) FcγRIIB (inhibitory Fc receptor, ITIM-containing), (3) SHIP-1 (phosphatase, opposes PI3K), (4) SHP-1 (phosphatase, dephosphorylates BCR signaling proteins). Expect enhanced BCR signaling: increased calcium flux, higher CD69/CD86, increased proliferation.

AUM Advantage: Negative regulators set BCR activation threshold and prevent autoimmunity (self-reactive B cell activation). Knockdown models loss-of-function mutations that cause autoimmune diseases. CD22 is emerging CAR-T target (CD22-CAR for CD19-relapsed B-ALL).

Antibody Production and Class Switching (3 applications)

Study class switch recombination, somatic hypermutation, and plasma cell biology

AID-Mediated Class Switch Recombination

Approach: Knockdown AID (AICDA, activation-induced cytidine deaminase) [8] in activated B cells undergoing class switching. Stimulate with CD40L + IL-4 (induces IgG1 switch). Measure: (1) germline transcripts (Iγ1 by qRT-PCR; induced before switch, AID-independent), (2) surface IgG1 expression (flow cytometry; requires AID), (3) secreted IgG1 (ELISA). AID knockdown blocks switch recombination (cells remain IgM+) but allows germline transcription (separates transcriptional priming from recombination) [8].

AUM Advantage: AID is master regulator of antibody diversification [8] and is required for class switching AND somatic hypermutation. Genetic dissection validates AID requirement and identifies AID-independent vs. AID-dependent steps. Relevant for antibody optimization: enhancing AID activity increases antibody affinity (somatic hypermutation).

Plasma Cell Differentiation Pathways

Approach: Knockdown transcription factors controlling B-to-plasma cell transition [9]: (1) BLIMP1/PRDM1 (master plasma cell factor, represses PAX5); knockdown prevents differentiation, (2) IRF4 (required for BLIMP1 expression and plasma cell maturation), (3) XBP1 (unfolded protein response transcription factor required for ER expansion and antibody secretion), (4) PAX5 (maintains B cell identity, represses plasma cell genes); knockdown accelerates differentiation. Differentiate with CD40L + IL-21, measure plasma cell markers (CD27high CD38high CD138+), intracellular Ig, and secreted Ig.

AUM Advantage: Plasma cell differentiation is terminal decision and irreversible [9]. Genetic dissection identifies master regulators vs. downstream effectors. BLIMP1 knockdown completely blocks differentiation (validates as master regulator). XBP1 knockdown allows differentiation but reduces antibody secretion (separates differentiation from function).

Somatic Hypermutation Mechanisms

Approach: Knockdown somatic hypermutation machinery in germinal center-like B cells: AID (initiates mutation by deaminating cytosine to uracil), UNG (uracil N-glycosylase, creates abasic site), MSH2/MSH6 (mismatch repair proteins, extend mutations). Culture with CD40L + IL-4 for 7-10 days, sequence immunoglobulin variable regions. AID knockdown eliminates mutations, UNG knockout reduces mutations to C/G transitions only, MSH2 knockout reduces mutations at A/T positions.

AUM Advantage: Somatic hypermutation generates antibody diversity in germinal centers and increases affinity 10-100 fold. Genetic dissection defines pathway steps. Relevant for antibody engineering: modulating mutation machinery can accelerate affinity maturation in vitro.

Autoimmune Disease Mechanisms (2 applications)

Model B cell contributions to autoimmune pathology

BAFF/APRIL Pathway and B Cell Survival

Approach: Knockdown BAFF-R (TNFRSF13C, receptor for BAFF/BLyS) in B cells. BAFF is critical B cell survival factor and provides anti-apoptotic signals through NF-κB2 (non-canonical pathway). BAFF-R knockout causes apoptosis in naive and transitional B cells within 24-48h. Test rescue by overexpressing BCL2 or BCL-XL (downstream anti-apoptotic proteins). Relevant for autoimmune diseases: excess BAFF promotes self-reactive B cell survival (lupus, rheumatoid arthritis). Belimumab (anti-BAFF antibody) approved for lupus.

AUM Advantage: BAFF pathway is validated therapeutic target. Genetic knockdown confirms BAFF-R requirement for B cell survival and validates BAFF blockade rationale. Can test BAFF-independent survival pathways (identify escape mechanisms).

Regulatory B Cell (Breg) Function

Approach: Knockdown IL-10 or TGF-β in regulatory B cells (CD24high CD38high or CD1dhigh CD5+ subsets). Bregs suppress autoimmunity by secreting IL-10 and TGF-β. Co-culture IL-10-knockout Bregs with autoreactive T cells; expect loss of suppression (T cells proliferate and produce inflammatory cytokines). Test in autoimmune disease models: myelin-reactive T cells (MS model) and collagen-reactive T cells (RA model).

AUM Advantage: Regulatory B cells are emerging therapeutic target for autoimmunity. Genetic validation of IL-10 requirement confirms Breg mechanism. Can test Breg enhancement strategies (IL-10 overexpression, expand Bregs) for cell therapy approaches.

Emerging CAR-B Cell Engineering (1 applications)

Engineer antibody-secreting B cells for continuous therapeutic antibody production

CAR-B Cells for Continuous Antibody Delivery

Approach: Engineer B cells to express CAR targeting tumor antigens (e.g., HER2-CAR), differentiate to plasma cells, and secrete CAR as soluble antibody. Unlike CAR-T (cell-mediated killing), CAR-B provides continuous antibody production. Knockdown BLIMP1 to maintain B cell state during expansion, then remove ASO to allow plasma cell differentiation and antibody secretion. Test antibody secretion kinetics (ELISA), tumor cell binding (flow cytometry with tumor cells + CAR-B supernatants), and ADCC (tumor cells + CAR-B antibodies + NK cells).

AUM Advantage: CAR-B is emerging alternative to CAR-T and provides continuous antibody rather than cell-mediated killing. AUMsilence enables optimization: control differentiation timing (BLIMP1 knockdown during expansion), enhance antibody secretion (XBP1 modulation), and prevent exhaustion. Transient knockdown allows testing before permanent engineering.

Frequently Asked Questions

Why are B cells so difficult to transfect?

B cells present multiple barriers to transfection: (1) Suspension cell biology with minimal endocytic activity; lipofection requires endocytosis, B cells have 5-10 fold lower endocytosis than adherent cells, resulting in <5% efficiency, (2) Severe electroporation sensitivity: 40-60% immediate cell death and membrane damage that disrupts BCR signaling (calcium dysregulation), (3) Rapid lysosomal degradation: efficient endosomal-lysosomal systems degrade delivered cargo before cytoplasmic release, (4) Transfection-induced activation artifacts: cationic lipids and electroporation trigger BCR-independent activation, calcium flux, and premature differentiation, confounding functional studies. These barriers make conventional transfection essentially impossible for B cell research.

Does AUMsilence affect BCR signaling or calcium flux?

No. AUMsilence treatment (2-5 μM, 72h) does not alter baseline BCR signaling capacity unless targeting signaling components directly. Validation: calcium flux assays (Indo-1 or Fluo-4) show normal anti-IgM-induced calcium response in ASO-treated B cells identical to untreated controls. Phospho-flow cytometry (phospho-SYK, phospho-BTK, phospho-PLCγ2) shows normal BCR signaling kinetics. Activation markers (CD69, CD86, HLA-DR) remain at baseline levels. This contrasts with electroporation (causes calcium dysregulation even without BCR stimulation) and lipofection (triggers activation within 4-6h). Preserved BCR signaling is essential for authentic studies of BCR pathways, anergy, tolerance, and signal thresholds.

Can I use AUMsilence in primary B cells and B cell lines?

Yes. AUMsilence sdASOs work effectively in both primary human B cells (CD19+ isolated from PBMCs, tonsils, lymph nodes) and established B cell lines (Raji, Daudi, BJAB, SU-DHL-4, JeKo-1). Primary B cells: use 2-5 μM ASO, requires survival signals (BAFF, APRIL, or CD40L) for extended culture. B cell lines: use 2-5 μM ASO, more robust in culture. Use primary B cells for translational studies, authentic BCR signaling, antibody production. Use B cell lines for screening, mechanistic studies, lymphoma biology (but validate key findings in primary B cells). Knockdown efficiency varies by target gene and cell type.

What concentration should I use for B cells?

Recommended starting concentration: 2-5 μM for both primary B cells and B cell lines. This is LOWER than T cells (10-15 μM) or macrophages (10 μM) because B cells are smaller with lower cytoplasmic volume. Lower concentration achieves equivalent intracellular ASO concentration with reduced off-target risk. Optimization range: 2-10 μM. Primary B cells: start at 5 μM, reduce to 2-3 μM if any toxicity observed. B cell lines: start at 2-3 μM (often sufficient due to rapid proliferation enhancing uptake). Test dose-response (2, 5, 10 μM) in initial experiments to identify optimal concentration for your target gene and application.

How do I validate BTK knockdown for ibrutinib comparison?

Multi-level validation comparing genetic knockdown to pharmacological inhibition: (1) Target validation: qRT-PCR (mRNA knockdown, 48h) and Western blot (BTK protein, 72h). (2) BCR signaling: stimulate with anti-IgM, measure calcium flux (BTK required for PLCγ2 activation), and phospho-flow for phospho-PLCγ2 and phospho-ERK. BTK knockdown reduces calcium flux, similar to ibrutinib treatment. (3) Cell survival: measure apoptosis (annexin V/7-AAD) in BCR-addicted lymphoma lines (ABC-DLBCL, CLL); BTK knockdown induces apoptosis and validates BTK dependency. (4) Proliferation: CFSE dilution or BrdU incorporation; BTK knockdown reduces proliferation in BTK-dependent lymphomas. Compare genetic knockdown vs. ibrutinib (1 μM, 48h) side-by-side; phenotypes should be concordant, validating BTK as ibrutinib target.

Can I study class switch recombination with AUMsilence?

Yes. AUMsilence is ideal for class switch recombination (CSR) studies: (1) AID/AICDA knockdown: blocks CSR (cells remain IgM+, cannot switch to IgG/IgA/IgE). Differentiates between transcriptional priming (AID-independent, measure germline transcripts Iγ, Iα) vs. recombination (AID-dependent, measure surface IgG, IgA). (2) Timing studies: add ASO before (Day 0) or during (Day 2-3) CSR induction with CD40L + IL-4. Tests if target required for CSR initiation vs. execution. (3) Downstream pathway dissection: knockdown UNG (uracil N-glycosylase) and MSH2/MSH6 (mismatch repair); required for CSR. (4) Readouts: flow cytometry (surface IgG, IgA), ELISA (secreted IgG, IgA), qRT-PCR (germline transcripts, post-switch transcripts), chromosome conformation capture (detect recombined loci). AUMsilence preserves B cell activation and proliferation (required for CSR) unlike electroporation (disrupts these processes).

How do I model CD19-negative relapse after CAR-T therapy?

Knockdown CD19 in B cell lymphoma lines (Raji, Daudi, patient-derived xenograft [PDX] cells) to model antigen-loss escape: (1) CD19 knockdown: treat with AUMsilence targeting CD19 (2-5 μM, 72h), validate by flow cytometry for surface CD19 reduction and Western blot for total CD19 protein. (2) Cell survival: measure viability and proliferation. Do lymphoma cells survive without CD19? If yes, predicts antigen-loss escape mechanism is viable. If apoptosis occurs, CD19 loss may not be resistance mechanism. (3) CAR-T co-culture: test CD19-knockdown lymphoma cells with CD19-CAR-T cells; expect reduced killing (CAR-T cannot recognize CD19-low cells). Quantify escape threshold. (4) Alternative target expression: measure CD22, CD79A, CD79B, and CD20 in CD19-low cells; identifies compensatory targets for CD19-relapse. (5) Signaling changes: CD19 is BCR co-receptor; knockdown may alter BCR signaling (measure calcium flux, phospho-flow). Tests if CD19 loss has functional consequences beyond CAR-T escape.

Can I knock down multiple genes simultaneously in B cells?

Yes. Multi-gene knockdown tests combinatorial effects and pathway redundancy. Strategies: (1) Dual oncogene knockdown: MYC + BCL6 (double-hit DLBCL model), MYC + BCL2 (Burkitt + apoptosis resistance), use 2-3 μM per ASO (total 4-6 μM for dual). (2) Pathway knockdown: BTK + SYK (redundant BCR kinases), CD79A + CD79B (BCR complex subunits). (3) Target + compensatory pathway: CD19 + CD22 (dual CAR-T target), CD20 + BAFF-R (survival pathways). Include single knockdown controls to assess individual vs. synergistic effects. Validate both targets knocked down (qRT-PCR, flow/Western). For >2 genes, consider pooled screening approach (knockdown 5-10 genes individually in parallel, identify hits, then test combinations).

Does AUMsilence work for plasma cell biology?

Yes, with caveats. Plasma cells are terminally differentiated, non-dividing antibody factories; ASO uptake may be lower than proliferating B cells. Strategies: (1) Pre-differentiation knockdown: add ASO at Day 0 (naive B cells), differentiate with CD40L + IL-21, and test function in Day 7 plasma cells. ASO persists through differentiation (plasma cells don't divide, no dilution). (2) Differentiation pathway studies: knockdown BLIMP1 (prevents differentiation), IRF4 (impairs maturation), or XBP1 (reduces antibody secretion). Measure plasma cell markers (CD27high CD38high CD138+), intracellular Ig, and secreted Ig. (3) Plasmablast studies: target earlier stage (Day 3-5 plasmablasts, still proliferating); easier ASO uptake than Day 7 plasma cells. (4) Primary plasma cells: isolate from bone marrow (CD138+), challenging culture (short-lived ex vivo), use within 2-3 days. For mature plasma cells, consider alternative approaches (siRNA electroporation with specialized electroporation systems; optimized for plasma cells but still high toxicity).

How do I study autoimmune B cell mechanisms with AUMsilence?

Model autoreactive B cell biology and therapeutic targets: (1) BAFF pathway: knockdown BAFF-R in B cells; induces apoptosis (BAFF is survival factor). Models belimumab (anti-BAFF antibody, approved for lupus). Test if autoreactive B cells more dependent on BAFF than normal B cells (potential therapeutic window). (2) Regulatory B cells (Bregs): isolate CD24high CD38high or CD1dhigh CD5+ Bregs, knockdown IL-10 or TGF-β. Co-culture with autoreactive T cells; IL-10-knockout Bregs lose suppressive function (T cells proliferate and produce inflammatory cytokines). Validates Breg mechanism. (3) BCR signaling threshold: knockdown negative regulators (CD22, FcγRIIB, SHIP-1); enhances BCR signaling, models loss-of-function mutations that cause autoimmunity (hyper-responsive B cells activate to self-antigens). (4) Tolerance mechanisms: knockdown BCL2 or BCL-XL in anergic B cells (self-reactive but functionally silenced); tests if tolerance maintained by active survival signals or passive neglect. (5) B-T co-cultures: knockdown CD40, CD80, or CD86 (co-stimulatory molecules) in B cells presenting self-antigen to T cells; tests B cell APC function in autoimmunity.

Peer-Reviewed Scientific References

All claims in this guide are supported by peer-reviewed publications. References are organized by topic for easy navigation.

[1] Seifert M, Küppers R. Human memory B cells. Leukemia. 2016;30(12):2283-2292. | PMC5148770

[2] Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15(3):149-59. | View Article

[3] Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier JC. B cell antigen receptor signaling 101. Mol Immunol. 2004;41(6-7):599-613. | View Article

[4] Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18(3):148-167. | PMC5808482

[5] Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14(4):219-32. | View Article

[6] Choi MY, Kipps TJ. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012;18(5):404-10. | PMC3722452

[7] Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359-68. | View Article

[8] Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102(5):553-63. | View Article

[9] Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160-71. | View Article

[10] Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002;2(12):920-32. | View Article

[11] Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298-310. | View Article

[12] Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-858. | View Article

[13] Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. Burkitt's lymphoma. Lancet. 2012;379(9822):1234-44. | PMC4967840

[14] Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015;15(3):172-84. | View Article

[15] Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22-35. | PMC3345192

[16] Basso K, Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol. 2010;105:193-210. | View Article

[17] Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228(4706):1440-3. | View Article

[18] Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, de Moerloose B, Nemecek ER, Bittencourt H, Hiramatsu H, Buechner J, Davies SM, Verneris MR, Nguyen K, Bader P, Balduzzi A, Bueno D, Strahm B, Webster H, Hayes-Jordan A, Janssen W, Negre E, Aerts J, Locatelli F, Chan LC, Balderas RS, Casolino C, Briones J, Kufe DW, Ishida Y, Zwaan CM, Nichols KE, Raetz EA, Teachey DT, Cario G, Halene S, Harrison CJ, Jeha S, Horwitz S, Maris JM, van der Lugt J, Mullighan CG, Pajtler KW, Reshef R, Rosenthal J, Shah N, van der Klift M, Pulsipher MA, Muffly LS, Sorensen PH, Alexander S, Meisel R, Ancliff P, Chiesa R, Vora A, Rives S. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504-1506. | PMC6187079

[19] Köhrer K, Janz S. B cell receptor malfunction links interleukin-7 receptor (IL-7R)- and interleukin-5 (IL-5)-dependent b lymphomas. Genes (Basel). 2020;11(4):461. | PMC7230905

[20] Fusil F, Calattini S, Amirache F, Mancip J, Costa C, Robbins JB, Salaun E, Theze J, Pèlegrin M, Cosset FL, Verhoeyen E. A lentiviral vector allowing physiologically regulated membrane-anchored and secreted antibody expression depending on B-cell maturation status. Mol Ther. 2015;23(11):1734-47. | PMC4817841

[21] Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46-51. | View Article

[22] Crooke ST, Liang XH, Baker BF, Crooke RM. Antisense technology: A review. J Biol Chem. 2021;296:100416. | PMC8005817

[23] Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell TA III, Rahdar M, Mukhopadhyay S, Hart CE, Bell M, Riney S, Hung G, Luo W, Greenlee S, Crooke ST. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol. 2019;37(6):640-650. | View Article

[24] Juliano RL, Carver K, Cao C, Ming X. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. Bioconjug Chem. 2012;23(2):147-157. | PMC3288458

[25] Miller CM, Donner AJ, Blank EE, Egger AW, Kellar BM, Østergaard ME, Seth PP, Harris EN. Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Nucleic Acid Ther. 2018;28(2):86-96. | PMC5899299

[26] Crooke ST. Molecular Mechanisms of Antisense Oligonucleotides. Nucleic Acid Ther. 2017;27(2):70-77. | PMC5372764

[27] Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-Targeted Therapeutics. Cell Metab. 2018;27(4):714-739. | View Article

[28] Vickers TA, Crooke ST. The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA. Nucleic Acids Res. 2015;43(18):8955-8963. | PMC4605327

[29] Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259-93. | View Article

[30] Akimova T, Zhang T, Negorev D, Singhal S, Stadanlick J, Rao A, Annunziata M, Levine MH, Beier UH, Diamond JM, Cantu E, Lal P, Hancock WW. FOXP3 transcription factor enhances CD39 enzymatic activity and suppressive function in human regulatory T cells. Front Immunol. 2024;15:1426657. | PMC11371716

Ready to Advance Your B Cell Research?

Discover how AUMsilence enables authentic BCR signaling studies, B cell lymphoma research, and antibody production mechanisms without transfection artifacts. Our scientists can help design your B cell experiments.

Order AUMsilence sdASO Request Custom ASO Design Consult Our Scientists